Lymph-T Exp® – Lymph Node Dry T Cell Expansion Technology Platform

Using Sinorda's proprietary T-cell production technology, it is possible to expand anti-tumor active T cells derived from lymph nodes to a scale of tens of billions within approximately two weeks (achieving an expansion of more than 5,000-fold), while maintaining the polyclonality, tumor-specificity, and T-cell stemness of the cell product. The success rate for preparation exceeds 90%.

Platform features:

● High proliferation efficiency

● Abundant TCR clones

● Maintaining T cell stemness